UK Markets open in 5 hrs 42 mins

Pharma Mar, S.A. (0RC6.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
100.70+1.05 (+1.05%)
At close: 04:27PM GMT

Pharma Mar, S.A.

Avenida de los Reyes, 1
Pol. Industrial La Mina – Norte Colmenar Viejo
Madrid 28770
Spain
34 91 846 60 00
http://www.pharmamar.com

Sector(s)
Industry
Full-time employees443

Key executives

NameTitlePayExercisedYear born
Mr. Jose Maria Fernandez Sousa-FaroFounder, Exec. Chairman, CEO & Pres294kN/AN/A
Mr. Pedro Francisco Fernandez PuentesExec. Vice-Chairman124kN/AN/A
Mr. Juan Carlos-Torres CarreteroFounderN/AN/A1949
Ms. María Luisa de Francia CaballeroChief Financial OfficerN/AN/AN/A
Mr. Pascal BesmanChief Operating OfficerN/AN/AN/A
Ms. Elena Calleja CrespoDirector of Fin. & Admin.N/AN/AN/A
Mr. José Luis Moreno Martinez-LosaDirector of Capital Markets & Investor RelationsN/AN/AN/A
Ms. Sandra Llamera SánchezGlobal Compliance HeadN/AN/AN/A
Ms. Maria Concepcion SanzBus. Legal DirectorN/AN/AN/A
Mr. Juan NoguésDirector of Marketing and SalesN/AN/AN/A
Amounts are as of 31 December 2015, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, rest of Europe, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops clinical-stage programs, including PM184 and PM14. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.

Corporate governance

Pharma Mar, S.A.’s ISS governance QualityScore as of 1 July 2021 is 6. The pillar scores are Audit: 4; Board: 8; Shareholder rights: 7; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.